Major pharmaceutical company GlaxoSmithKline, alongside smaller company XenoPort inc. released a statement this week saying that their diabetes drug Solzira failed to pass a Phase 2 study to treat diabetic neuropathy damage to the extremities of the body.
However, the response may be down to statistical glitch caused by an unexpectedly high placebo-response rate. According to XenoPort, placebo response of this nature is not uncommon when it comes to diabetic peripheral neuropathy, and can easily cause the failure of a trial.

The drug is yet to be reviewed or approved by the Food and Drug Administratio, to which it has been submitted as a treatment for restless leg syndrome. Diabetic neuropathy is an extremely common diabetes complication, caused when fluctuations in blood sugar levels damage nerve endings throughout the peripheral extremities of the body.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…